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Abstract
Mephedrone is a drug of abuse marketed as ‘bath salts". There are discrepancies concerning its long-term effects. We have
investigated the neurotoxicity of mephedrone in mice following different exposition schedules. Schedule 1: four doses of
50 mg/kg. Schedule 2: four doses of 25 mg/kg. Schedule 3: three daily doses of 25 mg/kg, for two consecutive days. All
schedules induced, in some animals, an aggressive behavior and hyperthermia as well as a decrease in weight gain.
Mephedrone (schedule 1) induced dopaminergic and serotoninergic neurotoxicity that persisted 7 days after exposition. At
a lower dose (schedule 2) only a transient dopaminergic injury was found. In the weekend consumption pattern (schedule
3), mephedrone induced dopamine and serotonin transporter loss that was accompanied by a decrease in tyrosine
hydroxylase and tryptophan hydroxylase 2 expression one week after exposition. Also, mephedrone induced a depressive-
like behavior, as well as a reduction in striatal D2 density, suggesting higher susceptibility to addictive drugs. In cultured
cortical neurons, mephedrone induced a concentration-dependent cytotoxic effect. Using repeated doses for 2 days in an
elevated ambient temperature we evidenced a loss of frontal cortex dopaminergic and hippocampal serotoninergic
neuronal markers that suggest injuries at nerve endings.
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Introduction
Mephedrone (4-methylmethcathinone) is a synthetic ring-
substituted cathinone often marketed as ‘‘bath salt’’. It appears
to be used by people involved in the dance and music scene and
also used more broadly by many young adults and adolescents [1].
It is known to have similar effects to other psychostimulant drugs
[2,3] but many users consider the effects of cathinones to be
superior to cocaine and MDMA (3,4-methylenedioxymethamphe-
tamine) [4,5]. Moreover, the abuse potential of cathinone
derivatives is comparable with that of cocaine or MDMA [6].
Based in its chemical structure, mephedrone is expected to elicit
stimulant effects similar to amphetamines [1,7]. It has been
demonstrated that mephedrone acts as a substrate for monoamine
transporters [8,9], which induces transporter-mediated depolariz-
ing current [10] and releases monoamines by reverse transport
[11]. Different authors [12–14] have shown that mephedrone
administration to rats increases extracellular dopamine (DA) and
serotonin (5-HT) in rat brain, similar to the effects of MDMA. All
these results evidenced that this drug interacts with DA and 5-HT
transporters displaying a similar pattern to other amphetamine
derivatives.
After a first dose, mephedrone users evidenced a desire to re-
dose, leading them to ingest large amounts of the drug [15]. This
pattern of use implicates a potential risk of overdosing [16,17].
Patients seeking medical attention after bath salts intoxications can
display agitation, psychosis, tachycardia, and also hyperthermia, a
commonly reported acute adverse effect of MDMA and beta-keto-
amphetamine ingestion in humans [18–20].
The use of this substance in a chronic pattern may also be
associated with more subtle long-term effects on brain neurotox-
icity. However, there are discrepancies concerning its neurotox-
icity in rodents. As with MDMA [21], it is possible that
mephedrone could display a species-dependent neurotoxicity.
Then, it is essential to compare results without losing sight of the
species in which experiments are conducted. To date, authors
found that mephedrone does not damage DA or 5-HT systems
when administered to mice [22,23]. Nevertheless, the studies did
not extent the evaluation of DA to brain areas other than striatum
or were performed with a drug exposure schedule not adjusted to
mephedrone pharmacokinetics [24].
The aim of this paper was to investigate the neurotoxicity profile
of mephedrone in mice, addressing some of the limitations in the
literature. Most authors described the neurotoxic effects of
methamphetamine three days after exposition [25] and those of
MDMA seven days after [26]. We examined the neurotoxic injury
induced by mephedrone at 3 and 7 days after finishing the
exposition. Obtaining as much mechanistic information as possible
regarding mephedrone, as well as on its neurotoxic effects, is of the
essence. In this regard, we have evaluated the in vivo effect of this
cathinone following different dosage schedule whilst complement-
ing it by performing in vitro experiments. With regards to MDMA,
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it is described that the magnitude of the acute hyperthermic
response plays a major role in determining the severity of the
consequences of its misuse, in such a way that ingesting the drug in
hot, crowded dance club conditions, increases the possibility of
subsequent cerebral neurotoxic effects [27]. To simulate these
usual conditions of drug exposure, the neurotoxicity studies with
amphetamine-derivatives are usually performed at elevated
ambient temperatures. Accordingly, present experiments were
carried out at high room temperatures. This condition was not
considered in previous published papers.
In the present study we used adolescent mice, a feature that
correlates with young adult consumers. We demonstrate that
mephedrone induces an injury at nerve endings in the frontal




Pure racemic mephedrone hydrochloride was synthetized and
characterized by us as described previously [7]. The other drugs
were obtained from Sigma-Aldrich (St. Louis, MO, USA).
[3H]ketanserin, [3H]paroxetine, [3H]raclopride and
[3H]WIN35428 were from Perkin Elmer Life Sci. (Boston, MA,
USA). All buffer reagents were of analytical grade.
Animals and ethics statement
The Experimental protocols were approved by the Animal
Ethics Committee of the University of Barcelona, following the
guidelines of the European Community Council (86/609/EEC).
Male Swiss CD-1 mice (Charles River, Spain) aged 4–5 weeks (25–
30 g) were used. Animals were housed at 2261uC under a 12 h
light/dark cycle with free access to food and drinking water.
In vivo neurotoxicity assays
No information about the subcutaneous doses in humans is
available. The only approach would be the doses used intranasally
that can reach up to 125 mg in each insufflation. The typical
amount of mephedrone consumed over an evening/night was
about 0.5 to 1 gram, usually taken in doses of 100-200 mg every
hour or two hours [28]. In our case a dose of 25 mg/kg in mice
corresponds to a 2 mg/kg in an adult. This mice equivalent dose
was calculated following the body surface area normalization
method [29]. The interval of 2 h between doses was chosen
according the mephedrone half-life [24].
Mice were administered subcutaneously (under the loose skin on
their back) according the following schedules. Schedule 1: four
doses of saline (5 ml/kg) or mephedrone (50 mg/kg) with a 2 h
interval. Mephedrone doses higher than 4650 mg/kg were not
tested to avoid cardiotoxicity-associated complications [30].
Schedule 2: four doses of saline or mephedrone (25 mg/kg) with
a 2 h interval. Schedule 3: three doses of saline or mephedrone
(25 mg/kg) with a 2 h interval, for two consecutive days. Rectal
temperatures were measured 45 min after the last dose by
inserting into the rectum (1.5 cm) a lubricated, flexible rectal
probe attached to a digital thermometer (Panlab, Barcelona,
Spain). Rectal temperature was measured 40 s after insertion of
the probe. During the expositions, the animals remained one per
cage, were maintained in an ambient temperature of 2662uC and
were kept under these conditions until 1 h after the last daily dose.
After initial results, we consider that schedule 3 was the most
suitable and representative of weekend dosing. So, different
parameters have been evaluated only in that schedule.
The doses of mephedrone used in this study were based on
results from Angoa-Pe´rez et al. [22], who concluded that, in mice,
a 4620 mg/kg regimen does not elicit neurotoxicity in striatal DA
nerve endings. Despite the importance of these results, it remains
of the essence to assess other exposition regimens and their effects
on several brain areas or neurotransmitters. In this sense, we
focused on simulating weekend use patterns (prolonging the days
of exposure but reducing the number of daily doses).
Tissue sample preparation
Crude membrane preparation (collecting both synaptosomal
and endosomal fraction) was prepared as described [31] with
minor modifications. Mice were killed by cervical dislocation at 3
or 7 days after exposition. Hippocampus, striatum and frontal
cortex were quickly dissected out and stored at 280uC until use.
When required, tissue samples were thawed and homogenized at
4uC in 20 volumes of buffer (5 mM Tris-HCl, 320 mM sucrose)
with protease inhibitors (aprotinin 4.5 mg/ml, 0.1 mM phenyl-
methylsulfonyl fluoride, and 1 mM sodium orthovanadate). The
homogenates were centrifuged at 1,000 g for 15 min at 4uC.
Aliquots of the resulting supernatants were stored at 280uC until
use for Western blot experiments. The rest of the samples were
resuspended and centrifuged at 15,000 g for 30 min at 4uC. The
pellets were resuspended in buffer and incubated at 37uC for
5 min to remove endogenous neurotransmitters. The protein
samples were recentrifuged. The final pellets were resuspended in
the appropriate buffer and stored at 280uC until use in
radioligand binding experiments. Protein content was determined
using the Bio-Rad Protein Reagent.
We performed an additional experiment. Following decapita-
tion, the brain of some animals was separated in the two
hemispheres. In one of them we applied a cellular fractionation
[32] to obtain a fraction with a high content in plasma membrane
and a second one enriched with endosomes. In the other
hemisphere we followed the standard method described above to
obtain a crude membrane fraction.
DA and 5-HT transporter density
The density of the DA transporter in striatal or frontal cortex
membranes was measured by [3H]WIN35428 binding assays.
These were performed in tubes containing 250 or 500 ml of 5 nM
[3H]WIN35428 in phosphate-buffer and 50 or 100 mg of
membranes, respectively. Incubation was done for 2 h at 4uC
and non-specific binding was determined in the presence of 30 mM
bupropion. All incubations were finished by rapid filtration under
vacuum through Whatman GF/B glass fiber filters. Tubes and
filters were washed rapidly three times with 4 ml of ice-cold buffer,
and the radioactivity in the filters was measured by liquid
scintillation spectrometry.
The density of the 5-HT transporter in the hippocampal and
frontal cortex membranes was quantified by measuring the specific
binding of 0.05 nM [3H]paroxetine after incubation with 150 mg
of protein at 25uC for 2 h in a Tris-HCl buffer. Clomipramine
(100 mM) was used to determine non-specific binding.
Western blotting and immunodetection
A general western blotting and immunodetection protocol was
used to determine tyrosine hydroxylase (TH) and tryptophan
hydroxylase 2 (TPH2) levels. For each sample, 20 mg of protein
was mixed with sample buffer (0.5 M TrisHCl, pH 6.8, 10%
glycerol, 2% (w/v) SDS, 5% (v/v) 2-b-mercaptoethanol, 0.05%
bromophenol blue), boiled for 5 min, and loaded onto a 10%
acrylamide gel. Proteins were then transferred to polyvinylidene
fluoride (PVDF) sheets (Immobilon-P; Millipore, USA). PVDF
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membranes were blocked overnight with 5% defatted milk in Tris-
buffer plus 0.05% Tween-20 and incubated for 2 h at room
temperature with a primary mouse monoclonal antibody against
TH (Transduction Lab, Lexington, KY, USA) 1:5000 or with a
primary rabbit polyclonal antibody against TPH2 (Millipore,
Billerica, MA, USA) 1:1000 and anti-(phosphor-Ser-19)TPH2.
After washing, membranes were incubated with a peroxidase-
conjugated antimouse IgG antibody 1:2500 or with a peroxidase-
conjugated antirabbit IgG antibody (GE Healthcare, Buckingham-
shire, UK) dil. 1:5000. Immunoreactive protein was visualized
using a chemoluminescence-based detection kit (Immobilon
Western, Millipore, USA) and a BioRad ChemiDoc XRS gel
documentation system (BioRad, Hercules, CA, USA). Scanned
blots were analyzed using BioRad Image Lab software and dot
densities were expressed as a percentage of those taken from the
control. Immunodetection of beta-actin (mouse monoclonal
antibody, 1:2500) served as a control of load uniformity for each
lane and was used to normalize differences due to protein content.
5-HT2A and D2 receptor density
The density of 5-HT2A receptors was measured in frontal
cortex membranes one week after their exposure to schedule 3.
Assays were performed in tubes containing 1 nM [3H]ketanserin
and 100 mg of membranes. Incubation was carried out at 37uC for
30 min in a Tris–HCl buffer. Methysergide (10 mM) was used to
determine non-specific binding. Assays to measure the density of
D2 receptors in striatum membranes of the same animals were
performed in tubes containing 2 nM [3H]raclopride and 50 mg of
membranes. Incubation was carried out at 25uC for 1 h in a Tris–
HCl buffer. Sulpiride (300 mM) was used to determine non-specific
binding.
Immunohistochemistry
Animals were anaesthetized with sodium pentobarbital (60 mg/
kg, i.p.) and perfused through the heart with 4% paraformalde-
hyde in 0.1 M phosphate buffer (1 ml/g of body weight). Brains
were removed and post-fixed for 2 h in the same solution,
cryoprotected in 30% sucrose/phosphate buffer for 24 h and
frozen in dry ice-cooled isopentane. Serial coronal sections (30 mm
thick) through the whole brain were cut in a cryostat and collected
in phosphate buffer. Free-floating sections were incubated for
15 min in H2O2 (0.3% phosphate buffer, 10% methanol).
Thereafter, sections were incubated in a blocking solution (1%
fetal bovine serum, 0.2 M glycine plus 0.5% Triton X100). After
blocking with 10% normal serum and 0.2% bovine serum
albumin, sections were rinsed and incubated overnight at 4uC
using a monoclonal antibody against fibrillary acidic protein
(GFAP, 1:1000) (Dako, Denmark). Sections were washed and
incubated with a biotinylated secondary antibody (1:200 Sigma-
Aldrich) for 2 h at room temperature. Afterwards sections were
incubated with avidin-biotin-peroxidase complex (ABC; 1:200;
Vector, Burlingame, CA, USA). Peroxidase reaction was devel-
oped with 0.05% diaminobenzidine in 0.1 M phosphate buffer
and 0.02% H2O2, and immunoreacted sections were mounted on
gelatinized slides. Stained sections were examined under a light
microscope (Olympus BX61).
Neuronal cell cultures
Primary neuronal cultures of cerebral cortex were obtained
from mouse embryos (E-16-18). The cerebral cortex was dissected,
meninges were removed, and tissue was incubated for 20 min in
trypsin (0.05%) at 37uC. Trypsin was inactivated with fetal bovine
serum and tissue was triturated with a Pasteur pipette. Dissociated
cells were washed with phosphate buffer containing 0.6% glucose
and centrifuged at 500 g for 5 min. The cells were redissociated in
Neurobasal medium (Invitrogen, Carlsbad, CA, USA) with
0.5 mM Lglutamine, sodium bicarbonate (0.04%) and 1 mg/ml
penicillin and streptomycin, containing B27 supplement and 10%
horse serum (HS). Neurons were plated at 0.4 million cells/ml in
96-well plates precoated with 1 mg/ml poly-L-lysine. Cultures
were maintained at 37uC in an incubator with 5% CO2. 24 h
after, cells were treated with arabinosylcytosine (10 mM) to prevent
the growth of glial cells. The culture medium was changed after 4
days to Neurobasal medium with B27 without antioxidants. Before
treating the cells, the HS concentration was reduced by half. The
cultures were used for experiments after 8–9 days in vitro with
different concentrations of mephedrone and different times of drug
exposure.
Cell viability
Cell viability was assessed using the MTT (3-(4,5-dimethylthia-
zole-2-yl)-2,5diphenyltetrazoliumbromide) method. This assay was
carried out as described by Verdaguer et al. [33] with minor
modifications. MTT was added to a final concentration of 250 mM
and cells were incubated for 2 h [34]. Cell viability was expressed
as a percentage of the absorbance measured in untreated cells.
Forced swimming test (FST)
The immobility time in FST was measured by an observer blind
to the exposition using the procedure described by Porsolt et al.
[35]. Briefly, mice were placed individually in a glass cylinder
(height 21 cm, diameter 12 cm) containing water at 2561uC up to
a height of 15 cm. Animals were randomly divided into two
groups (12–16 animals/group) and treated with saline or
mephedrone and tested 1, 3 or 7 days after schedule 3. Each
animal was recorded for 6 min and the total period of immobility
(in seconds) was measured. A mouse was judged to be immobile
when it remained floating in water, making only the necessary
Table 1. Effect of mephedrone on weight gain.
Schedule
Group 1 2 3
Saline 0.7160.14 0.8460.22 0.7760.21
Mephedrone 20.9960.14a 20.9860.16a 21.2360.20b
Data are expressed (mean 6S.E.M) as the difference in body weight, in grams, between the end (24 h after the last dose) and the beginning (prior to the first dose) of
the exposure.
asig. diff. (p,0.01) vs. Saline.
bsig. diff. (p,0.001) vs. Saline.
doi:10.1371/journal.pone.0099002.t001
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movements to keep its head above the surface. Each mouse was
used only once for each experimental session [36].
Statistical analysis
All data are expressed as mean 6 standard error of the mean
(S.E.M.). Differences between groups were compared using one-
way ANOVA or Student-t test for independent samples.
Significant (p,0.05) differences were then analyzed by Tukey’s
post hoc test for multiple means comparisons where appropriate.
Statistic calculations were performed using Graph Pad Instat
(GraphPad Software, San Diego, USA). Analysis of concentration-
viability curves was performed using non-linear regression
(InvivoStat software [37]). Experimental values to calculate IC50
were in the linear region of the sigmoid curve (between 25 and
85% of the maximum effect).
Results
Lethality
Initial experiments were carried out with 6 animals per cage.
With this condition, lethality was of about 70%. Thereafter, all
experiments carried out in this study were performed with a single
animal per cage. The number of fatalities of mephedrone-treated
mice was similar in schedule 2 (8.33%) and 3 (10.17%), and
slightly higher in schedule 1 (14.28%). It is important to note that
all mephedrone schedules induced the occurrence, in some
animals, of a stereotypy (repeated self-licking of the ventral base
of the neck) that continued with self-bites and led to the
appearance of injuries in that zone.
Effect of mephedrone on body temperature and weight
gain
In the present study, drug expositions were performed in
animals housed singly at a high room temperature. All mephe-
drone schedules induced a significant increase in body tempera-
ture. Hyperthermia was apparent in schedule 1 (saline:
36.460.1uC; mephedrone: 38.160.1 p,0.001) and schedule 2
(saline: 36.760.1uC; mephedrone: 37.460.2uC p,0.01). Results
obtained from schedule 3 showed that mephedrone–induced
hyperthermia was more intense after the last dose in the first day of
exposition (saline: 36.760.1uC; mephedrone 38.160.1, first day;
vs. saline: 36.460.1uC; mephedrone 37.5 60.3, second day, p,
0.001). Mephedrone exposure slowed the weight gain compared
with saline-treated animals (Table 1). Moreover, 3 days after
finishing all schedules, the animals recovered their body weight
(data not shown).
Effect of mephedrone on different in vivo markers of DA
and 5-HT neurotoxicity
Schedule 1: At 3 and 7 days post-exposition, mephedrone
induced a significant loss in DA reuptake sites of about 50% in
Figure 1. Effect of a mephedrone exposure (4 doses of 50 mg/kg, s.c. at 2 h interval) on dopamine transporter density, measured as
[3H]WIN35428 binding in mouse striatum (A), or frontal cortex (B) and 5-HT transporter density, measured as [3H]paroxetine
binding, in hippocampus (C) and frontal cortex (D). Results are expressed as mean6S.E.M. from 8–10 animals. *p,0.05; **p,0.01 and ***p,
0.001 vs. saline.
doi:10.1371/journal.pone.0099002.g001
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mouse striatum and frontal cortex membranes (Fig. 1A and 1B).
Additionally, mephedrone-exposed mice showed a transient
decrease in [3H]paroxetine binding in the frontal cortex that
disappeared four days later (Fig. 1D). By contrast, the decrease of
[3H]paroxetine binding in the hippocampus was apparent both 3
and 7 days after exposition (Fig. 1C).
Schedule 2: 3 days after the drug regimen, the frontal cortex was
the only area where a marker showed a significant decrease. For
this reason, the specific binding of [3H]WIN35428 in this area,
was also evaluated 4 days later. At this time, DA transporter
density returned to basal levels (Fig. 2B). Mephedrone did not
modify [3H]WIN35428 binding in the striatum (Fig. 2A) or the
[3H]paroxetine binding neither in the hippocampus nor in the
frontal cortex (Fig. 2C and 2D).
Schedule 3: The suppressive effect of mephedrone on striatal
[3H]WIN35428 binding was transient and returned later to basal
values (Fig. 3A). However, in frontal cortex, the same marker
suffered a significant loss (about 40%) evident 3 and 7 days post-
exposition (Fig. 3B). Because these results pointed to a real injury
more than to a transient regulation, we investigated the expression
of the TH. We found a relationship between the decrease in the
[3H]WIN35428 specific binding and the decrease in enzyme
expression in the frontal cortex (saline: 100.0062.46%; mephe-
drone: 60.0469.34% p,0.01, 3 days after exposition and
55.3069.11% p,0.001, 7 days after exposition).
To characterize the recovery of the DA transporter marker in
striatum, we assessed radioligand binding in the plasma membrane
and in the endosomal fractions. Mephedrone elicited a reduction
in [3H]WIN35428 binding in the plasma membrane (saline:
100.0066.49%; mephedrone: 65.8069.00% p,0.01) and the
corresponding increase in the endosome fraction (saline:
100.00610.51%; mephedrone: 127.4365.94% p,0.05). Conse-
quently, when a redistribution of transporter occurred, we did not
find a loss of radioligand binding in the crude membrane
preparation.
The reduction of 5-HT terminal markers in mephedrone-
treated animals was sustained and significant in the frontal cortex
(Fig. 3D), and especially pronounced (50%) in the hippocampus
after 7 days (Fig. 3C). Consequently, we analyzed another
biochemical marker of terminal integrity, TPH2, and its Ser-19
phosphorylated form. In hippocampus, the decrease of [3H]par-
oxetine binding runs in parallel with a decrease of the total TPH2
(Fig. 4A). In frontal cortex, this expression was lower but not
significant (Fig. 5A). In both experiments, the shape of the TPH2
band obtained from mephedrone-treated animals shows differ-
ences that can be attributed to a protein modification. As protein
phosphorylation in Ser-19 has been described as a frequent
mechanism that regulates TPH2 function, we proceeded to
determine it. In both brain areas, the remaining enzyme was
phosphorylated in the mephedrone group with respect to saline
(Fig. 4B, 4C, 5B, 5C).
Effect of mephedrone on astroglial activation
To assess the presence of astroglial activation, immunohisto-
chemistry studies were carried out with the glial-specific marker,
Figure 2. Effect of a mephedrone exposure (4 doses of 25 mg/kg, s.c. at 2 h interval) on dopamine transporter density, measured as
[3H]WIN35428 binding in mouse striatum (A), or frontal cortex (B) and 5-HT transporter density, measured as [3H]paroxetine
binding, in hippocampus (C) and frontal cortex (D). Results are expressed as mean6S.E.M. from 8–10 animals. **p,0.01 vs. saline.
doi:10.1371/journal.pone.0099002.g002
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GFAP. There were no signs of striatal or cortical astroglial
activation in mephedrone-treated animals. In the hippocampus,
some astrocytes with the typical stellate morphology were observed
in control animals, but an apparent increase in GFAP immuno-
reactivity could be seen in the dentate gyrus of the hippocampus in
the mephedrone group, implying reactive astrocytes (Fig. 6).
Depressant-like effect of mephedrone
In schedule 3, mephedrone significantly increased the immo-
bility time in the FST as compared with saline group
(F3,44 = 5.509, p,0.01). Post hoc Tukey’s means comparison test
demonstrated that 3 days post-exposition mephedrone significantly
increased the immobility time (saline: 125.43611.83 s; mephe-
drone: 217.83619.55 s p,0.001). This increase was still signifi-
cant 7 days post-exposition (178.80622.45 s p,0.05). Moreover,
mephedrone exposure failed to influence the immobility time in
FST 24 h after the last administration (Fig. 7).
Effect of mephedrone on D2 and 5-HT2A receptor
density
To determine the involvement of striatal DA D2 receptors, we
measured [3H]raclopride binding in this brain area. Mephedrone
(schedule 3) decreased the number of these receptors in mouse
striatum (saline: 100.0066.49%; mephedrone: 79.8665.46% p,
0.05, 3 days after exposition and 78.5767.42% p,0.05, 7 days
after exposition). Similarly, mephedrone-exposed animals showed
a decrease in the number of 5-HT2A receptors in frontal cortex
(saline: 100.0066.28%; mephedrone: 67.4163.07% p,0.001)
and hippocampus (saline: 100.0068.45%; mephedrone:
71.7064.02% p,0.01), 3 days after exposition. However, the
density of these receptors returned to basal values on day 7
(98.8164.01% and 98.9364.10%, respectively).
Effect of mephedrone on cultured cortical neuron
viability
The exposition of mouse cortical cultured cells to various
concentrations of mephedrone (from 80 mM to 1 mM) for 24 h or
48 h caused a concentration-dependent decrease in metabolically
active cells, as assessed by the MTT assay. The calculated LD50
value for mephedrone after 24 h of incubation was
242.72640.66 mM which was higher (p,0.01) to that obtained
after 48 h of drug exposure (115.94616.58 mM).
Discussion
The easy availability of cathinones and their initial status as
legal highs may have contributed to their increasing popularity as
drugs of abuse. Because of the relatively short history of the use of
cathinones as recreational drugs, their effects among long-term
users have yet to be determined. Based on its structural similarity
to well established neurotoxic psychostimulants such as metham-
phetamine and MDMA, it was hypothesized that mephedrone
would exert neuronal damage. However, there are important
discrepancies concerning the neurotoxicity induced by cathinones
[8,22,38]. The inconsistent results could be attributed to
Figure 3. Effect of a mephedrone exposure (3 doses of 25 mg/kg, s.c. at 2 h interval for 2 days) on dopamine transporter density in
mouse striatum (A), or frontal cortex (B) and on 5-HT transporter density in hippocampus (C) and frontal cortex (D). Results are
expressed as mean6S.E.M. from 8–10 animals. *p,0.05; **p,0.01 and ***p,0.001 vs. saline.
doi:10.1371/journal.pone.0099002.g003
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differences in species, dosage, administration route or ambient
temperature.
Some cases of aggressive behavior, even cannibalism, as a
consequence of exposure to new designer drugs have been recently
reported in the media. However, these cases have been poorly
documented [39]. In the present study, all mephedrone schedules
induced the appearance of initial stereotypy consisting in repeated
self-licking that was followed by aggressive behavior which leads to
self-injuries. This is an especially important factor to be taken into
account, seeing as it required animals to be housed individually. It
is a feature described for the first time, but it has been also
reported following high doses of methamphetamine or d-
amphetamine [40–41], but not MDMA involving DA and 5-HT
system in this abnormal behavior. Fantegrossi et al. [42] reported
self-injurious behavior following methylenedioxypryrovalerone
administration only at high, but not normal, ambient temperature,
suggesting a potential role of the ambient temperature in this
behavior. Further studies are needed to determine the mechanism
implicated in this feature induced by mephedrone and its
relationship with the exposed dose.
Temporal development of body weight of mice was studied to
ascertain an easily measurable effect of mephedrone. Like other
amphetamines, animals treated with mephedrone experienced a
reduction in weight gain that was only transient seeing as values
returned to basal values 3 days after finishing the corresponding
exposure.
Hyperthermia is a commonly reported acute adverse effect of
amphetamines [43] and beta-keto-amphetamine ingestion in
humans [19]. Rodent exposure to cathinones also cause significant
increases in core temperature [8,23,44,45]. The temperature has
been examined during administration of multiple doses of the
drug. Probably the strain of mouse, the dose and the ambient
temperature can influence the size and direction of the
hyperthermic response observed in the present experiments.
Although lethal hyperthermia was not observed at the assessed
dosages in mice, present results demonstrate that at high ambient
temperatures, mephedrone impaired the thermoregulatory re-
sponse; this effect persisted throughout the two day exposition.
Nevertheless further research is required in order to characterize
whether the role of hyperthermia is complementary or essential in
the advent of mephedrone-induced neurotoxicity.
Several studies established a controversy concerning the
neurotoxic effect of mephedrone in DA and 5-HT systems.
Angoa-Pe´rez and co-workers [22] concluded that mephedrone
administration to C57/BL6 mice at doses up to 40 mg/kg did not
damage DA nerve endings in the striatum. In that study, no
information regarding the ambient temperature is provided.
Moreover, Hollander et al. [23] demonstrated that mephedrone
exposure (30 mg/kg, twice daily for 4 days) to rats and mice
resulted in no significant changes in brain monoamine levels.
Conversely, Hadlock et al. [38] reported a rapid decrease in DA
and 5-HT transporter function after mephedrone administration
Figure 4. Effect of a mephedrone exposure (3 doses of 25 mg/kg s.c. at 2 h interval for 2 days) on total tryptophan hydroxylase
TPH2 expression (A) and its phosphorylated form (B) in hippocampus. Panel C shows a representative Western blot. Results are expressed
as mean6S.E.M. from 8–10 animals. *p,0.05 and **p,0.01 vs. saline.
doi:10.1371/journal.pone.0099002.g004
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(four doses of 10 or 25 mg/kg) to Sprague-Dawley rats at an
ambient temperature of 27uC. However, other investigators have
failed to find any persistent neurochemical impact of mephedrone
dosing with long duration dosing protocols [46].
In the effort to model recreational mephedrone use, we
considered it appropriate to simulate the widespread practices of
‘‘stacking’’ (taking multiple doses at once in order to increase the
desired effect and/or overcome tolerance from prior use) and
‘‘boosting’’ (taking supplemental doses over time in order to
maintain the drug effect). For this reason, we chose to administer
multiple doses of mephedrone during each exposition day. In
schedule 3 we repeated the exposition the next day, simulating a
pattern of a recreational weekend use.
It is important to note that we corroborated that the crude
membrane preparation used in the present experiments collects
both the synaptosomal membrane and the endosomal fraction;
consequently it is not possible to ascertain whether or not a
transporter redistribution was taking place when observing no
decrease in radioligand binding in crude membrane preparations.
We demonstrate that mephedrone, administered at doses (i.e.
schedule 1) that mimic a high exposure in humans (around 1.5 g/
session) [47], induced an important decrease in DA transporter
density in mouse striatum and frontal cortex membranes that
persisted 7 days after exposition. This effect was accompanied by a
Figure 5. Effect of a mephedrone exposure (3 doses of 25 mg/kg s.c. at 2 h interval for 2 days) on total tryptophan hydroxylase 2
expression (A) and its phosphorylated form (B) in frontal cortex. Panel C shows a representative Western blot. Results are expressed as
mean6S.E.M. from 8–10 animals. *p,0.05 vs. saline.
doi:10.1371/journal.pone.0099002.g005
Figure 6. Representative hippocampal expression of glial
fibrilliary acidic protein (GFAP). Sections of the dentate gyrus
(64 A, B;620, C, D) from mice exposed to saline (A, C) or mephedrone
(3 doses of 25 mg/kg given subcutaneously for 2 days) (B, D). The
animals were sacrificed 7 days after the last dose.
doi:10.1371/journal.pone.0099002.g006
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significant loss of 5-HT transporters in the hippocampus.
However, at these high doses, acute cardiovascular toxicity of
mephedrone is likely [30] and probably outweighs neurotoxic
effects.
The subsequent experiments were carried out at a lower dose
(25 mg/kg). Schedule 2 dosage schedule only elicited a transient
decrease in cortical DA transporter, suggesting a temporary
regulatory effect. Moreover, no significant loss of 5-HT transporter
in the frontal cortex or the hippocampus was found.
Schedule 3 (three doses of 25 mg/kg for two consecutive days)
can be considered the most representative because it is closest to
the typical weekend consumption pattern. After this exposure,
mephedrone induced loss of DA and 5-HT transporters that were
especially apparent in the frontal cortex and the hippocampus
respectively. The monoamine deficit induced by this schedule was
also characterized by a significant decrease of each enzymatic
marker that correlated with the decrease in radioligand binding.
TH and TPH catalyze the first and rate-limiting step in the
biosynthesis of DA and 5-HT respectively. The isoform TPH2 is
responsible for 5-HT biosynthesis in the brain. Post-translational
modifications have been shown to regulate the protein function.
The enzyme is known to be phosphorylated on Ser-19 by both
protein kinase A and Ca2+/calmodulin dependent protein kinase
II in vitro. This modification results in increased stability and
activity [48]. The decrease in transporter binding and enzyme
levels, jointly with astrogliosis, point to an injury at the nerve
endings; the increase in Ser-19TPH2 in mephedrone-treated
animals seems to reflect a compensatory mechanism in the
undamaged 5-HT terminals
The recovery of DA transporter levels in mouse striatum after 7
days of exposition raises the question on whether the decrease in
[3H]WIN35428 binding observed 3 days after exposition is an
effect of biochemical down-regulation in the absence of tissue
damage rather than being reflective of an injury. The non-
significant increase in astroglial activation observed in this area
was consistent with the absence of terminal injury and suggests
that the DA transporter gene expression may be negatively
regulated by mephedrone exposure. This is consistent with
previous results reporting that MDMA acts on 5-HT transporter
gene expressions [49]. Moreover, although DA transporter density
returns to basal values in crude membrane preparations 7 days
after exposition, results point to changes in DA levels in the striatal
synapses, seeing as there is a significant redistribution of this
transporter. A significant increase in transporter density is
observed in the endosomal fraction, together with a reduction in
membrane expression. Astrocytes stabilize and maintain homeo-
static repair of tissues and contribute to early wound repair [50].
In the present study, mephedrone-exposed animals showed an
increase in GFAP immunoreactivity in the dentate gyrus of the
hippocampus, which confirms the injury in this area.
Low 5-HT levels in the synapse have been linked to various
psychiatric disorders, including depression. In our study, mephe-
drone increased the immobility time in the forced swim test, which
indicates an increase in stress-related depressive behavior. This
effect was evident 3 and 7 days after exposition, and correlates
with the reduction of the neurochemical parameters. This is in
accordance with results from McGregor et al. [51] who
demonstrated that MDMA-treated animals show higher immo-
bility and fewer active escape attempts in the forced swimming
model. To our knowledge, present results provide the first
preclinical data on this matter, and suggest that mice exposed to
a stacking and boosting regime of mephedrone could be more
prone to depressive-like symptoms.
Recently, it has been established that methamphetamine
exposure dysregulates D2mediated DA transmission in the
striatum [52]; Vidal-Infer et al. [53] also demonstrated that, in
adolescent mice, striatal DA D2 receptors are involved in the
rewarding properties of MDMA. Accordingly, we have studied the
alteration in the striatal density of these receptors after the third
mephedrone schedule. The density of D2 receptors remained
below control values both 3 and 7 days after mephedrone
exposition, pointing to an increase in the susceptibility of these
animals to drug addiction [54]. Moreover, we found a significant
transient decrease in the number of 5-HT2A receptors 3 days after
exposition, which can be reflective of a neuroadaptative response
to the increase in 5-HT release induced by mephedrone. These
results are in agreement with those reported by Scheffel et al. [55]
who demonstrated that the repeated administration of MDMA
causes transient down-regulation of 5-HT2 receptors, which are
predominantly abundant in the frontal cortex.
We performed in vitro studies in cortical cultured cells in order to
assess a theoretical concentration that could be injurious on
neuron viability, which is known to be quite high for most
amphetamines. In these cells we found a concentration-dependent
Figure 7. Effect of mephedrone on immobility time in mouse forced swim test. Animals were randomly divided into two groups (12–16
animals/group) and administered subcutaneously with saline (5 ml/kg) or mephedrone (3 doses of 25 mg/kg for 2 days) and tested 1, 3 or 7 days
after exposure. Each animal was recorded for 6 min and the total period of immobility (in seconds) was registered. Each mouse was used only once
for each experimental session. Each bar represents mean6S.E.M. immobility time. *p,0.05 and ***p,0.001 vs saline (one-way ANOVA and post hoc
Tukey test).
doi:10.1371/journal.pone.0099002.g007
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cytotoxic effect of mephedrone in neuronal viability, which
increases significantly with respect to time of drug exposure. It
must be pointed that this cytotoxicity is higher than that of
MDMA in primary cultures of hippocampal neurons [56].
According to our previous pharmacokinetic data of mephedrone
in rats [24], an i.v. dose of 10 mg/kg leads to an extrapolated
mephedrone blood concentration of about 5.6 mM. Then, a dose
of 25 mg/kg would correspond to a mephedrone concentration of
about 14 mM that is about 15 times lower than the LD50 in
cultured cortical cells. It is important to note that in the present
study, when exposing mice to 25 mg/kg of mephedrone no
neuronal death is suspected, as there were no signs of striatal or
cortical astroglial activation in mephedrone-exposed animals.
Only, some reactive astrocytes were appreciated in the dentate
gyrus. Additionally, we did not observe microglial activation (data
not shown). Results from cortical cultured cells seem to point in
the same direction because neuronal death is obtained at higher
concentrations than those reached after in vivo exposure. Nonethe-
less, as occurs with MDMA, we cannot exclude the possibility that
some of its metabolites may cause toxic effects of this nature, since
the in vivo metabolic pathway of mephedrone is similar to that of
MDMA [57].
Finally, our results demonstrate that mephedrone-induced brain
injury differs according to exposition schedule (dose, number of
administrations and intervals). Neuronal toxicity elicited by
mephedrone is apparent when administered in 2 h intervals. This
is in accordance with our previous paper characterizing the
pharmacokinetics of mephedrone [24]. Using this dose interval
and repeated doses for 2 days, in an elevated ambient
temperature, we found a loss of frontal cortex dopaminergic and
hippocampal serotoninergic neuronal markers together with
astrogliosis, pointing to the presence of injuries at nerve endings.
A compensatory mechanism runs in parallel with this process,
including an increase in the phosphorylated form of TPH2, a
different subcellular distribution of DA transporter, and a decrease
in D2 receptors.
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